No 03 2023

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for market authorization of Oczyesa, octreotide subcutaneous depot, for the maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

Cellevate, Fraunhofer IBMT (Institute for Biomedical Engineering), and the German bioreactor company OLS (Omni Life Science) have been awarded a EUR 1 million grant through the Eurostar program for large scale production of iPSCs (induced pluripotent stem cells).

In 2023, there were an estimated 263 million malaria cases, and 597,000 malaria deaths, making it a prioritized field for many researchers around the world. In Umeå, Sweden, Professor Oliver Billker’s group is focusing on the basic biology of the parasite, with the goal to develop new drugs and vaccines and understand why some mosquito species transmit malaria while others do not.

Leon Wyszkowski, president of analytical services for clinical research, has received the Key to Gothenburg, on behalf of Thermo Fisher during a ceremony at the City Hall.

Hansa Biopharma has announced the appointment of Renée Aguiar-Lucander as Chief Executive Officer (CEO), effective immediately.

The European Patent Office, EPO, has issued a decision to grant European patent for exidavnemab, a drug candidate being developed as a treatment for synucleinopathies such as Parkinson’s disease and Multiple System Atrophy (MSA).

Euro-BioImaging Finland, the research infrastructure of Finnish bioimaging, has received funding of about EUR 28 million from the Research Council of Finland.